For the Inventor, By the Inventor

Enter assignee name

Marseilles, France

Innate Pharma

USPTO Granted Patents = 66

CIPO Patents = 7

EPO Patents = 53

Trademarks = 3

Forward Citations = 240

Loading Chart...

Loading Chart...

68 inventors (with patents filed for the assignee):

Laurent Gauthier (36 out of 41 patents)

Carine Paturel (23 out of 24 patents)

Benjamin Rossi (20 out of 20 patents)

4. Mathieu Blery (12 out of 14 patents)

5. Nadia Anceriz (10 out of 10 patents)

6. Pascale Andre (10 out of 18 patents)

7. Nicolai Wagtmann (9 out of 13 patents)

8. Hélène Sicard (9 out of 9 patents)

9. Delphine Bregeon (8 out of 8 patents)

10. Ivan Perrot (7 out of 8 patents)

11. Ariane Morel (7 out of 7 patents)

12. Patrick Dennler (7 out of 7 patents)

13. Eliane Fischer (7 out of 7 patents)

14. Roger Schibli (6 out of 24 patents)

15. Christian Belmant (6 out of 14 patents)

Core Competencies:

T Cell Lymphoma

NKp46 Binding Agents

Multispecific NK Engager Protein

Humanized Antibodies

CD73 Blockade

KIR3DL2 Binding Agents

Siglec Neutralizing Antibodies

Combination Therapy

Cancer Treatment Regimens

NK Cell Activity Regulation

Enzymatic Conjugation

Peripheral T Cell Lymphoma

66 patents: Sort by Forward Citations

1. 12448442 - Treatment of T cell lymphoma (2025-10-21),

2. 12365731 - NKp46 binding agents (2025-07-22),

3. 12252543 - Multispecific NK engager protein (2025-03-18),

4. 12227569 - Humanized antibodies with increased stability (2025-02-18),

5. 12209126 - Treatment of cancer (2025-01-28),

6. 12202907 - Nucleic acids encoding and methods of producing proteins comprising antibody chains (2025-01-21),

7. 12084498 - Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma (2024-09-10),

8. 12037392 - Treatment regimens using anti-NKG2A antibodies (2024-07-16),

9. 11999784 - Treatment of peripheral T cell lymphoma (2024-06-04),

10. 11970535 - Treatment with anti-KIR3DL2 agents (2024-04-30),

11. 11958907 - CD73 blockade (2024-04-16),

12. 11891444 - Variable regions for NKp46 binding proteins (2024-02-06),

13. 11858990 - KIR3DL2 binding agents (2024-01-02),

14. 11845795 - NKp46 binding proteins (2023-12-19),

15. 11795222 - Treatment of head and neck cancer (2023-10-24),

Innate Pharma is a clinical-stage biotechnology company that specializes in developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases. Their innovative approach harnesses the innate immune system to fight diseases. With a diverse pipeline of drug candidates and partnerships with leading pharmaceutical companies, Innate Pharma aims to bring new treatment options to patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

66 Patents

#1 in Marseilles

#365 in France

#10,736 in the World

Marseilles, France

Innate Pharma

Forward Citations = 240

68 inventors:

Laurent Gauthier (36 out of 41 patents)

Carine Paturel (23 out of 24 patents)

Benjamin Rossi (20 out of 20 patents)

4. Mathieu Blery (12 out of 14 patents)

5. Nadia Anceriz (10 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…